// App-Quantinova.ai

TPS3167 : Phase II basket trial of olaparib and durvalumab in patients (pts) with isocitrate dehydrogenase (IDH) mutated solid tumors.

Researchers

Presenter

  • Eric Xueyu Chen

Principal Investigators

  • Grainne M. O'Kane

  • Warren P. Mason

  • Jennifer J. Knox

  • Albiruni Ryan Abdul Razak

  • Gelareh Zadeh

Medical Centers

  • Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, Canada

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • MacFeeters-Hamilton Centre for Neuro-Oncology Research, Princess Margaret Cancer Center, Toronto, ON, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Durvalumab

  • Olaparib

Outcome

  • N/A

Study Design

  • Single Arm

  • Cohort

Phase

  • NA

Study Id's

  • NCT03991832

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved